Biodexa Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Biodexa Pharmaceuticals has a total shareholder equity of £8.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £14.0M and £5.2M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
UK£0
Borç
Faiz karşılama oranı | n/a |
Nakit | UK£5.06m |
Eşitlik | UK£8.73m |
Toplam yükümlülükler | UK£5.24m |
Toplam varlıklar | UK£13.97m |
Son finansal sağlık güncellemeleri
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: BDRX's short term assets (£7.5M) exceed its short term liabilities (£3.5M).
Uzun Vadeli Yükümlülükler: BDRX's short term assets (£7.5M) exceed its long term liabilities (£1.8M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: BDRX is debt free.
Borcun Azaltılması: BDRX has no debt compared to 5 years ago when its debt to equity ratio was 4.4%.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: BDRX has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Tahmini Nakit Akışı: BDRX is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.